Late benefits 10-18 years after drug therapy for infection with Schistosoma haematobium in Kwale District, Coast Province, Kenya

American Journal of Tropical Medicine and Hygiene

Volumn 73, Issue 2, 2005, Pages 359-364

  Ouma, John H ^b   King, Charles H ^a   Muchiri, Eric M ^c   Mungai, Peter ^c   Koech, Davy K ^d   Ireri, Edmund ^d   Magak, Philip ^e   Kadzo, Hilda ^f  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASENO UNIVERSITY   (Kenya)

^c MINISTRY OF HEALTH   (Kenya)

^d KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^e City X Ray Services   (Kenya)

^f KENYATTA NATIONAL HOSPITAL   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISCHISTOSOMAL AGENT; PRAZIQUANTEL;

ADULT; ADULTHOOD; AGE; ARTICLE; BLADDER DISEASE; CHILDHOOD DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG CHOICE; ECHOGRAPHY; ENDEMIC DISEASE; FEMALE; HEMATURIA; HUMAN; HYDRONEPHROSIS; KENYA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIVARIATE ANALYSIS; PREVALENCE; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMIASIS; SEX DIFFERENCE; TREATMENT OUTCOME;

SCHISTOSOMA HAEMATOBIUM;

EID: 24644486043     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2005.73.359     Document Type: Article

References (25)

1. van der Werf MJ, de Vlas SJ, 2001. Morbidity and Infection with Schistosomes or Soil-Transmitted Helminths. Rotterdam: Erasmus University, 1-103.
2. Chen MG, Mott KE, 1989. Progress in assessment of morbidity due to Schistosoma haematobium infection. Trop Dis Bull 86: R1-R36.
3. Smith JH, Christie JD, 1986. The pathobiology of Schistosoma haematobium infection in humans. Hum Pathol 17: 333-345.
4. WHO, 1994. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, Liver Flukes and Helicobacter pylori. Geneva: World Health Organization.
5. King CH, 2001. Disease in schistosomiasis haematobia. Mahmoud AAF, ed. Schistosomiasis. London: Imperial College Press, 265-296.
6. King CH, Muchiri E, Ouma JH, Koech D, 1991. Chemotherapy-based control of schistosomiasis haematobia. IV. Impact of repeated annual chemotherapy on prevalence and intensity of Schistosoma haematobium infection in an endemic area of Kenya. Am J Trop Med Hyg 45: 498-508.
7. Hatz CF, Vennervald BJ, Nkulila T, Vounatsou P, Kombe Y, Mayombana C, Mshinda H, Tanner M, 1998. Evolution of Schistosoma haematobium-related pathology over 24 months after treatment with praziquantel among school children in southeastern Tanzania. Am J Trop Med Hyg 59: 775-781.
8. King CH, Muchiri EM, Ouma JH, 2000. Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya. Emerg Infect Dis 6: 585-594.
9. Gryseels B, 1989. The relevance of schistosomiasis for public health. Trop Med Parasitol 40: 134-142.
10. Tanner M, 1989. Evaluation of public health impact of schistosomiasis. Trop Med Parasitol 40: 143-148.
11. Muchiri EM, Ouma JH, King CH, 1996. Dynamics and control of Schistosoma haematobium transmission in Kenya: an overview of the Msambweni Project. Am J Trap Med Hyg 55(Suppl): 127-134.
12. Peters PAS, Kazura JW, 1987. Update on diagnostic methods for schistosomiasis. Mahmoud AAF, ed. Bailliere's Clinical Tropical Medicine and Communicable Diseases, Schistosomiasis. London: Bailliere Tindall, 419-433.
13. Richter J, Hatz C, Campagne G, Bergquist NR, Jenkins JM, 2000. Ultrasound in Schistosomiasis: A Practical Guide to the Standardized Use of Ultrasonography for the Assessment of Schistosomiasis-Related Morbidity. Geneva: World Health Organization.
14. Kleinbaum DG, Kupper LL, Morgenstern H, 1982. Epidemiologic Research: Principles and Quantitative Methods. New York: John Wiley & Sons.
15. Breslow NE, Day NE, 1980. Statistical Methods of Cancer Research. Volume 1. The Analysis of Case-Control Studies. Lyon, France: International Agency for Research on Cancer.
16. King CH, 2001. Epidemiology of schistosomiasis: determinants of transmission of infection. Mahmoud AAF, ed. Schistosomiasis. London: Imperial College Press, 115-132.
17. Allison PD, 1999. Logistic Regression Using the SAS System: Theory and Application. Gary NC: SAS Institute Inc.
18. Clennon JA, King CH, Muchiri EM, Kariuki HC, Ouma JH, Mungai P, Kitron U, 2004. Spatial patterns of urinary schistosomiasis infection in a highly-endemic area of coastal Kenya. Am J Trop Med Hyg 70: 443-448.
19. Abdel-Wahab MF, Esmat G, Ramzy I, Narooz S, Medhat E, Ibrahim M, El-Boraey Y, Strickland GT, 2000. The epidemiology of schistosomiasis in Egypt: Fayoum Governorate. Am J Trop Med Hyg 62: 55-64.
20. Warren KS, Mahmoud AAF, 1976. Targeted mass treatment: a new approach to the control of schistosomiasis. Trans Assoc Am Physicians 89: 195-204.
21. Wilkins HA, Goll P, Marshall TF, Moore P, 1979. The significance of proteinuria and haematuria in Schistosoma haematobium infection. Trans R Soc Trop Med Hyg 73: 74-80.
22. Pugh RN, Bell DR, Gilles HM, 1980. Malumfashi Endemic Diseases Research Project, XV. The potential medical importance of bilharzia in northern Nigeria: a suggested rapid, cheap and effective solution for control of Schistosoma haematobium infection. Ann Trop Med Parasitol 74: 597-613.
23. Stolley PD, Strom BL, 1986. Sample size calculation for clinical pharmacology studies. Clin Pharmacol Ther: 489-90.
24. Subramanian AK, Mungai P, Ouma JH, Magak P, King CH, Mahmoud AA, King CL, 1999. Long-term suppression of adult bladder morbidity and severe hydronephrosis following selective population chemotherapy for Schistosoma haematobium. Am J Trop Med Hyg 61: 476-481.
25. WHO, 2002. Prevention and control of schistosomiasis and soil-transmitted helminthiasis. Report of a WHO expert committee. World Health Organ Tech Rep Ser 912: 2-5.